New European Pulmonary Vascular Disease Symposium Launch
We cordially invite you to participate in the international, interdisciplinary “Pulmonary Hypertension Symposium – Update 2016”. A strength of this meeting is its multidisciplinary nature – bringing together basic-translational scientists and clinicans (cardiologists, pulmonologists, neonatologists, thoracic surgeons, intensivists). The first session and two of the three keynote lectures concentrate on basic mechanisms and genetics, the other 3 sessions have a strong clinical focus. This meeting will update you on recent discoveries and innovations, and addresses several important paradigm shifts in the field of pulmonary hypertension and heart failure:
Pulmonary vascular disease relates in large part to increased cell proliferation, metabolic dysfunction, resistance to apoptosis, and inflammation (rather than vasoconstriction) – "cancer hypothesis“.
The impact of epigenetic regulation and gene mutations on pulmonary arterial hypertension (PAH) phenotypes is increasingly recognized. In addition, stem cells, progenitor and differentiated blood cells play important roles in PAH development.
The right ventricle, and its interaction with the left ventricle, is the key determinant of prognosis in PAH. Thus, innovative, non-invasive imaging of the hypertensive RV-PA unit, and the search for direct RV treatment targets, are paramount.
The heterogenous pre- and postnatal etiologies and unique features of pediatric pulmonary hypertensive vascular disease justify specific expert consensus statements and recommendations that will be highlighted throughout this meeting.
Early bird registration closes on January 31st. You can register by clicking the side panel at the top of this page. For more information, please visit: